NEWSROOM

News & Stories


Newsroom

Press Releases

  • MammaPrint Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer

Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrintยฎ Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study

IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ€“ August 12, 2025 โ€“ Agendia, Inc., a leader in innovative genomic testing for breast cancer, today announced the publication of new findings in JNCI Cancer Spectrum validating Read More

  • ASCO 2025 Agendia Press Release

Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO Annual Meeting

FLEX Study Highlights Clinical Utility of MammaPrintยฎ and BluePrintยฎ in Diverse Patient Populations Across Breast Cancer Subtypesย  IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ€“ May 27, 2025 โ€“ Agendiaยฎ, Inc., a leader in precision Read More

Newsroom

News, Stories & Breast Cancer Blog

Breast Cancer Statistics 2024

Authors Angela N. Giaquinto MSPH | Hyuna Sung PhD | Lisa A. Newman MD, MPH | Rachel A. Freedman MD, MPH | Robert A. Smith PhD | Jessica Star MA, MPH | Ahmedin Jemal Read More

Who We Are

Our purpose, our story our vision. Hear how Agendia fits into the evolving landscape of technology and cancer care.

Two women reading about genomic breast cancer results

Latest Data

Agendia Presents New Data Demonstrating MammaPrintโ€™s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients [โ€ฆ]

I Am Here breast cancer illustration

Patient News

Agendia and artist Andrea Caceres go โ€œbeyond the mammogramโ€ in a portrait series illustrating people touched by breast cancer.